Sixth Annual Seizure Action Plan Awareness Week to Promote Seizure Preparedness Nationwide, Feb. 9-16, 2026
UCB Canada remains dedicated to helping patients and working collaboratively with CDA-AMC following draft recommendation for (Pr)BIMZELX® for hidradenitis suppurativa (HS) [Yahoo! Finance]
PrBIMZELX® (bimekizumab injection) approved in Canada for treatment of moderate to severe hidradenitis suppurativa (HS) [Yahoo! Finance]
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting